Fox Run Management, L.L.C. C4 Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.05 - $8.1 $108,373 - $216,747	-26,759 Reduced 64.12%	14,973 $69,000
Q1 2024 May 13, 2024	BUY	$5.3 - $11.0 $221,179 - $459,052	41,732 New	41,732 $340,000
Q2 2022 Aug 12, 2022	SELL	$5.06 - $26.46 $45,165 - $236,181	-8,926 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$19.99 - $33.23 $178,430 - $296,610	8,926 New	8,926 $217,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.